Vyome (HIND) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vyome is the larger company by market cap ($8.4 million vs $8.2 million), about 1.0 times the size. On valuation, Moleculin Biotech trades at a lower trailing P/E (0.0x vs 0.3x for Vyome).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | MBRX |
|---|---|---|
| Share price | $1.20 | $7.74 |
| Market cap | $8.42M | $8.22M |
| 1-day change | -17.24% | -2.40% |
| YTD return | -65.12% | — |
| 1-year return | -75.90% | — |
| 5-year return | -100.00% | — |
| P/E ratio (TTM) | 0.25 | 0.04 |
| EPS (TTM) | $4.77 | $179.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $319.71K | $0 |
| Revenue growth (YoY) | +24.43% | — |
| Net income (latest FY) | $-10.26M | $-33.56M |
| Gross margin | 68.43% | — |
| Operating margin | -3269.35% | — |
| Net margin | -3209.75% | — |
| 52-week high | $5.88 | $202.50 |
| 52-week low | $1.20 | $3.22 |
| Distance from 52-week high | -79.59% | -96.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +635.83% | +55.04% |
| Average volume | 13.92K | 44.66K |
| Shares outstanding | 7.02M | 1.06M |
| Employees | 9 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vyome trades at a higher earnings multiple (0.3x vs 0.0x trailing P/E).
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
HIND vs MBRX FAQ
Which is bigger, Vyome or Moleculin Biotech?
Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.22M for Moleculin Biotech (MBRX).
Which has the lower P/E ratio, HIND or MBRX?
MBRX has the lower trailing P/E at 0.0, versus 0.3 for HIND. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Vyome and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.